Sign Up
OverviewAPI
Bicycle Therapeutics is leading the development of targeted cancer therapeutics called Bicycle Toxin Conjugates (BTCs), with potential to improve patient outcomes in solid and hematological malignancies. Their lead candidate, BT1718, is showing promising results in phase 1/2 trials. The company aims to capture a significant market share, particularly in cancer, due to BTCs' enhanced therapeutic index compared to existing targeted biologics.

Ask a question